---
title: "Weekly Recap | Can-Fite BioPharma -34.41%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298096696.md"
description: "Can-Fite BioPharma (CANF) dropped 34.41% this week, closing at $2.23, down from $3.40 the previous Friday. Against a 0.09% rise in the S&P 500, CANF underperformed by about 34.5 percentage points. The daily bars show a steady slide: Monday opened at $3.42, the week’s high, and the price stepped lower over the next three sessions. Wednesday’s $2.36 close came with volume of roughly 20.3m shares, far above any other day, and Friday ended at the week’s low of $2.23."
datetime: "2026-09-05T06:31:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298096696.md)
  - [en](https://longbridge.com/en/news/298096696.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298096696.md)
generator: "portal-rs"
---

# Weekly Recap | Can-Fite BioPharma -34.41%, consensus target above spot

## The Week

Can-Fite BioPharma (CANF) dropped 34.41% this week, closing at $2.23, down from $3.40 the previous Friday. Against a 0.09% rise in the S&P 500, CANF underperformed by about 34.5 percentage points. The daily bars show a steady slide: Monday opened at $3.42, the week’s high, and the price stepped lower over the next three sessions. Wednesday’s $2.36 close came with volume of roughly 20.3m shares, far above any other day, and Friday ended at the week’s low of $2.23.

## Key Events

Wednesday, 2 September, carried the week’s heaviest news flow. Can-Fite first announced it had exercised warrants for about $4.0m in gross proceeds, then reported longer-than-expected survival in its Phase III Namodenoson liver cancer trial and said it was planning an earlier interim analysis. Intraday, the stock fell roughly 20% to 22% at various points. Thursday and Friday brought further disclosure that the company had cut the warrant exercise price to secure the $4m inducement financing. The trial data and the financing are the company-specific story; the share price pulled back alongside the dilution expectations.

## Analyst Ratings

One broker covers Can-Fite, with a buy rating. The consensus rating is strong buy, and the consensus target of $8 sits about 258.7% above the latest price of $2.23. The target range is a single point at $8, so there is no dispersion. Within the biotechnology sector, the stock ranks 498th out of 507 covered names.

## The Week Ahead

No company-specific earnings are scheduled in the coming week. On the macro side, US NFIB small business optimism arrives Tuesday 8 September, followed on Thursday 10 September by jobless claims, PPI, existing home sales, wholesale sales and a 10-year Treasury auction. For a low-liquidity name that has just pulled back sharply, the nearer-term watch is whether the post-financing price stabilises and whether the company gives a clearer timeline for the earlier interim analysis of its Phase III trial.

## In Short

The week’s tension sits between a consensus target of $8, more than 200% above spot, and a financing that lowered warrant exercise prices to raise about $4m, bringing dilution concerns. The price fell more than 30% on the week, with Wednesday volume unusually heavy. The valuation side shows a price-to-book of about 0.52 and a market value below $3m, a typical small-cap biotech profile. What matters next is the money flow after the financing and any fresh timing signal from the Namodenoson interim analysis.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Can-Fite Reports 10-Year Survival for Liver Cancer Patient in Namodenoson Phase II Study](https://longbridge.com/en/news/304848660.md)
- [Can-Fite Secures Eurasian Patent Allowance for Piclidenoson in Lowe Syndrome](https://longbridge.com/en/news/303952306.md)
- [Credo Technology Stock Is Surging Wednesday: What's Going On?](https://longbridge.com/en/news/305155753.md)
- [This Apple Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday](https://longbridge.com/en/news/305194106.md)
- [14 companies sold 108,247 Bitcoin in 2026, but here’s why it’s not what it looks like!](https://longbridge.com/en/news/305139945.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**